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Abstract
Background: As the eradication of tumor cells in vivo is most efficiently performed by cytolytic T
lymphocytes (CTL), various methods for priming tumor-reactive lymphocytes have been
developed. In this study, a method of priming CTLs with ultraviolet (UV)-irradiated tumor cells,
which results in termination of tumor cell proliferation, apoptosis, as well as upregulation of heat
shock proteins (HSP) expression is described.
Methods: Peripheral blood mononuclear cells (PBMC) were primed weekly with UV-irradiated or
mitomycin-treated RPMI 8226 multiple myeloma cells. Following three rounds of stimulation over
21 days, the lymphocytes from the mixed culture conditions were analyzed for anti-MM cell
reactivity.
Results: By day 10 of cultures, PBMCs primed using UV-irradiated tumor cells demonstrated a
higher percentage of activated CD8+/CD4- T lymphocytes than non-primed PBMCs or PBMCs
primed using mitomycin-treated MM cells. Cytotoxicity assays revealed that primed PBMCs were
markedly more effective (p < 0.01) than non-primed PBMCs in killing RPMI 8226 MM cells. Surface
expression of glucose regulated protein 94 (Grp94/Gp96) and Grp78 were both found to be
induced in UV-treated MM cells.
Conclusion: Since, HSP-associated peptides are known to mediate tumor rejection; these data
suggest that immune-mediated eradication of MM cells could be elicited via a UV-induced HSP
process. The finding that the addition of 17-allylamide-17-demethoxygeldanamycin (17AAG, an
inhibitor of HSP 90-peptide interactions) resulted in decreased CTL-induced cytotoxicity
supported this hypothesis. Our study, therefore, provides the framework for the development of
anti-tumor CTL cellular vaccines for treating MM using UV-irradiated tumor cells as immunogens.
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Background
Multiple myeloma (MM), a malignancy of terminally dif-
ferentiated plasma cells, is the most common hemato-
logic cancer in the United States (US) [1]. Currently, MM
is incurable and there is an urgent need for the develop-
ment of novel and curative forms of therapy, including
immunotherapy. A major limitation on the treatment of
all cancers is the evasion strategy developed by tumor cells
to bypass immune surveillance. Thus far, specific anti-cel-
lular therapy against MM has been difficult to develop
because of the down regulation of tumor cell surface anti-
gens (Ag) and the attenuation of host immunity by MM
cells. The majority of MM cellular immunotherapies have
focused on deriving anti idiotypic (Id) patient-specific
CTL [2-4]. Other strategies include the use of MM-specific
RNA transduced dendritic cells and MM apoptotic bodies
pulsed dendritic cells [5,6]. Unfortunately, although some
of these studies were promising none of them have
achieved high response rates and therefore have not been
actively pursued.
As eradication of tumor cells in vivo is most efficiently per-
formed by CD8+ and/or CD4-CD8- natural killer (NK)
cytolytic T lymphocytes (CTL) [7,8], various methods for
increasing recognition by lymphocytes have been devel-
oped. Since the success of such therapies depends signifi-
cantly on the efficiency of Ag presentation, tumor cells
have been genetically modified to present antigens
directly to tumor reactive T cells [9]. Other potentially
safer methods include the use of cytokines and/or adju-
vants to increase the antigenicity of the tumor itself or to
enhance the immune recognition of the tumor in vivo [2].
Reinfusion of tumor-specific CTLs as therapy against can-
cer (i.e. adoptive immunotherapy) has been used in the
treatment of a number of cancers [10] proving particularly
effective in some patients with melanoma [11]. Several
groups have also recently characterized a novel class of
cells that have potent innate anti-tumor properties termed
Cytokine Induced Killer (CIKs) [12] or Interferon-γ pro-
ducing Killer Dendritic Cells (IKDCs) [13]. Those as well
as newly developed anti-tumor cytolytic cells with NK cell
markers [14] demonstrate renewed interest in finding non
antigen-specific anti-tumor effector cells for cellular adop-
tive therapy.
Unfortunately, searches for novel tumor-associated
(TAAs) for many cancers have been extremely slow and
those that do exist have rarely translated into clinically
effective therapies [15]. Thus finding a source of tumor-
specific antigens with adjuvant properties that can be used
in an adoptive-immunotherapy setting to elicit strong T
cell responses is greatly desired. In a landmark paper by
Srivastava et al., tumor antigens were isolated from chem-
ically induced sarcomas and found to be capable of medi-
ating tumor rejection [16]. One of these tumor antigens
was identified as tumor rejection Ag-1 (TRA-1, gp96,
Grp94), a heat shock protein (HSP)-90 family member
[17], which is capable of mediating tumor rejection of var-
ious cancers. Heat shock proteins are induced when cells
are exposed to stress (e.g. DNA damage) [18], and have
now been intimately linked to antigen presentation path-
ways [19,20]. In fact, HSPs Grp94, HSP-90, and Grp78 are
known to carry peptides that are stimulatory to CD8+ CTL
via a process known as cross-presentation [21] and are
being currently used for immunotherapy [22-24]. Expres-
sion of HSP can be induced using ultraviolet (UV) light
irradiation [25], which damages DNA and triggers the
stress response in the cell [26]. Hence, we embarked on
this study to determine if UV-irradiation could be used as
a means to concomitantly increase HSP expression and
tumor cell antigenicity of MM cells, resulting in the pro-
duction of effective anti-tumor CTLs. We demonstrate that
UV-irradiation indeed induces total RNA, protein, as well
as surface expression of Grp94 and Grp78, two potent
immunogenic HSPs. Furthermore, UV-irradiated MM
cells were shown to be effective in priming CD8+ CTL and
resulted in efficient induction of anti-MM CTL in-vitro.
Finally, recognition of the UV-irradiated tumor cells by
the CTL was partially inhibited by the ansymcin antibiotic
17-AAG, an HSP-protein inhibitor [9,16,18].
Methods
Cells
The human RPMI 8226 MM (CCL-155) cell line was pur-
chased from American Type Culture Collection (ATCC,
Rockville, MD) and cultured in complete media consist-
ing of 90% RPMI 1640 with L-glutamine media, 10% fetal
bovine serum (FBS), 25 IU/ml penicillin, 25 μg/ml strep-
tomycin, and additional 5 mM L-glutamine. Normal
human peripheral blood (PB) was obtained from volun-
teer donors with informed consent and under institu-
tional review board (IRB) approval (Singapore General
Hospital, IRB approval #103/2003). Peripheral blood
mononuclear cells (PBMCs) were isolated using Ficoll-
Hypaque (Amersham Pharmacia, Uppsala, Sweden) den-
sity gradient sedimentation and cultured in complete
media. Cell cultures were maintained at 37°C with 5%
CO2 in a humidified atmosphere. Cells were enumerated
using standard trypan blue (Gibco BRL, Life Technologies,
Carlsbad, CA) exclusion assays.
UV-irradiation of RPMI 8226 MM cell line
UV-irradiation was performed using the Stratagene Strata-
linker UV Crosslinker (Stratagene, La Jolla, CA). For vari-
ous experiments, UV-irradiation (6 mJ/cm2 to 240 mJ/
cm2) was performed on open 10 cm diameter tissue cul-
ture dishes containing RPMI 8226 MM cells (1.5 × 106 in
3.0 mL of complete media).
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Cell proliferation assays
Cell proliferation was assessed using DNA synthesis assay.
Here, standard tritiated thymidine (3H-TdR, Perkin Elmer
Life Sciences, Boston, MA) incorporation assays were per-
formed. Cells (5,000 cells/mL) were first incubated with
0.25 μCi/well overnight and then treated for 3 hrs in 96-
well tissue culture plates (200 μL/well) with various doses
of UV-irradiation or left untreated. Next, cells were har-
vested onto fiberglass filters using a cell harvester (Tomtec
Mach III Auto, Tomtec, Hamden, CT) and counted on a
beta plate reader (Wallac 1450 MicroBeta TriLux, Turku,
Finland). Each proliferation result is an average of three
independent experiments. Readings are expressed as
counts per minute (CPM) and derived from triplicate val-
ues for each condition. No proliferation was observed in
long-term cultures for cells exposed to 120 mj/cm2 or
above UV-irradiation.
Annexin V/propidium iodide (PI) staining
In order to assay for the presence of apoptosis, RPMI 8226
MM cells (1 × 105/sample) were dually stained using flu-
orescein isothiocynate (FITC) labeled annexin V (annexin
V-FITC) and PI (BD Pharmingen, San Diego, CA) accord-
ing to the protocol provided by the manufacturer. Briefly,
cells were washed and suspended in 100 μL of binding
buffer, then stained using 5 μL of annexin V-FITC and 2 μL
of PI. Analysis was performed on the Cytomics FC500
flow cytometric analyzer (Beckman Coulter, Miami, FL).
In this assay, annexin V+/PI- cells represent MM cells in
early stages of apoptosis, whereas dually positive annexin
V+/PI+ cells are MM cells that have undergone apoptosis.
Data from each flow histogram quadrant (Annexin-V
FITC detected in the first channel and PI in the second
channel) is then tabulated and represented as % apoptosis
in chart form.
Priming of PBMCs under 'mixed-culture' conditions
Priming of PBMCs was performed by co-culture of PBMCs
(5 × 105/well) and UV-irradiated (120 mJ/cm2, 5 × 106/
well) or mitomycin (100 μg/ml, 5 × 106/well) treated
RPMI 8226 MM cells in 6-well tissue culture plates. Thus
the responder cell to stimulator cell ratio was 1:10. Cell
co-cultures were maintained in complete media with
recombinant human interleukin-2 (IL-2, R & D Systems,
Minneapolis, MN, 0.5 ng/mL). Weekly priming (Days 0,
7, 14, 21 and 28) was performed by adding UV-irradiated
or mitomycin-treated RPMI 8226 MM cells (5 × 106/well)
into the respective existing co-culture. Half-media
exchanges containing IL-2 were performed every 3 days to
5 days. Cells were collected and washed weekly before
each 'mixed-culture' priming was performed.
Indirect fluorescence flow cytometric analysis
T cell subset immunophenotyping and HSP expression
were performed using indirect fluorescence flow cytomet-
ric analysis (Cytomics FC500 flow cytometric analyzer,
Beckman Coulter). The following mouse anti-human
monoclonal antibodies (mAbs) were used for effector cell
immunophenotyping -anti-CD8, anti-CD45, anti-CD56,
anti-granzyme A, and anti-perforin (Beckman Coulter).
Antibodies were directly conjugated with fluorophores
(FITC and phycoerythrin (PE)). Lymphocytes were identi-
fied as CD45bright plus low side-scatter cells. For assess-
ment of heat shock protein expression, goat anti-Grp78
(C-20, sc-1051) and goat anti-Grp94 (C-19, sc-1794)
(both from Santa Cruz Biotechnology, Santa Cruz, CA)
were used. The secondary antibody used (where appropri-
ate) was donkey anti-goat FITC mAb (Santa Cruz). Briefly,
primed PBMCs or UV-irradiated RPMI 8226 MM cells (0.5
× 106 to 1.0 × 106/sample) were harvested, washed three
times in phosphate buffered saline (PBS), blocked with
10% human AB serum in PBS, and stained using the
appropriate mAb at 4°C for 30 mins. Next, cells were
washed three times in PBS prior to analysis. Statistical
analysis was performed using the Chi-squared test (Micro-
soft Excel, Microsoft Office 97, Microsoft Corp., Red-
mond, WA).
CTL assay
A tritiated thymidine (3H-TdR)-based cytotoxicity assay
(JAM assay) was used to evaluate the killing of viable
RPMI 8226 MM cells by primed and non-primed PBMCs
[27]. In this assay, 3H-TdR is first incorporated into DNA
during labeling. During analysis, degraded DNA is
washed through a fiberglass filter, leaving behind the
intact, high molecular weight DNA. Briefly, RPMI 8226
MM cells (target cells, T) were first labeled with 3H-TdR
(10 μCi/ml, PerkinElmer Life Sciences, Waltham, MA
USA) for 12 hrs in 96-well tissue culture plates (2 × 104
cells/well). Primed or non-primed PBMCs (effector, E)
were co-cultured with target cells at various E:T (0:1, 25:1,
50:1, 75:1 or 100:1) ratios for various times. Next, cells
were harvested onto fiberglass filters using a cell harvester
(Tomtec Inc. Hamden, CT USA) and counted on a beta
plate reader (PerkinElmer,). The percentage of specific
killing relative to medium-stimulated controls was calcu-
lated as [(Spontaneous – Experimental)/Spontaneous] ×
100], where the radioactivity (cpm) in T cells exposed to
control medium was defined as S and that of treated cells
was defined as E [28].
Western immunoblotting
Whole cell extracts (WCE) were obtained from non-UV-
irradiated and UV-irradiated RPMI 8226 MM cells (3.0 ×
106 cells/sample) using EBC1 lysis buffer, which contains
50 mM Tris pH 8.0, 150 mM NaCl, 0.1% NP-40, 0.5 μg/
mL phenylmethylsulfonyl fluoride (PMSF), 50 mM NaF,
1 mM NaVO4, and a Complete® protease inhibitor tablet
(Roche Diagnostics GmbH, Mannheim, Germany) in
every 50 mL. Proteins were quantified using Bradford's
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method (Bio-Rad, Hercules, CA), and resolved (20 μg/
lane) in a 12% sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) gel. Next, proteins were
transferred to a polyvinylidene fluoride (PVDF) mem-
brane (Schleicher & Schuell, Keene, NH), and blocked for
2 hrs using Tris-buffered saline (TBS) – 20 mM Tris pH
7.6, 150 mM NaCl – containing 1.0% Tween-20 (Sigma-
Aldrich, St Louis, MO). Membranes were probed using
goat anti-Grp78 (C-20, sc-1051) or goat anti-Grp94 (C-
19, sc-1794) mAbs 1:200 dilution (Santa Cruz Biotech-
nology, Santa Cruz, CA) for 1 hr, then washed thrice with
TBS containing 0.2% Tween-20 (TBST), and then rep-
robed using horseradish peroxidase (hrp)-conjugated
donkey anti-goat IgG mAb 1:15,000 dilution (Santa Cruz
Biotechnologies) for 2 hrs. Next, membranes were washed
6 times with TBST, and chemiluminescene detection was
preformed using ChemiGlow® reagents and filmless imag-
ing on the FluoChem Imager™ (both from Alpha
Innotech, San Leandro, CA). Spot densitometry was per-
formed using AlphaEaseFC™ software (Alpha Innotech).
In some cases, to determine relative expression, the nor-
malized values for each condition were derived by taking
the integrated density values from the protein in question
and dividing that by the values for Actin in that condition.
Quantitative Real Time Reverse Transcription PCR (Q-
PCR)
RNA was extracted from the RPMI 8226 MM cell line
using the RNeasy RNA Extraction Kit (Qiagen Gmb,
Hilden, Germany) according to the manufacturer's rec-
ommendations, and quantified using the GeneQuant Pro
Kit (Amersham Biosciences, Piscataway, NJ). Quantitative
real time revere transcription-PCR (250 ng of RNA/sam-
ple) was performed using the Roche LightCycler® system
(Roche Diagnostics, 20 μL/reaction) for grp78 using the
following primers (25 nM each primer): 5'-CCCTCAC-
TATGAATGGGT-3' (forward), and 5'-GTGATCTCGGCT-
CACT-3' (reverse); as well as grp94 using the following
primers: 5'-CTGAAAAAGGGCTATGAAGT-3' (forward),
and 5'-CCTTGCCGGTTTGGTA-3' (reverse). Amplification
of β-actin was used as an internal control; 5'-ATCT-
GGCACCACACCTTCTAGCAA TGAGCTGCG-3' (for-
ward); 5'-CGTCATACTCCTGCTTGCTGA
TCCACATCTGC-3' (reverse). Reaction conditions were
94°C 1 s denaturation, 64°C 1 s annealing, and 72°C 15
s extension; for a total of 40 cycles. Human grp94 and
grp78 as well as, β-actin PCR efficiencies were calculated
as 10-1/slope, where the slope of the line was determined
from the relationship between PCR crossing point and the
logarithm of concentration. The adjusted efficiencies for
each gene was determined by 5 individual tissue samples
diluted over five 10-fold concentrations. The relative ratio
for each HSP was calculated using unknown and calibra-
tor RNA using the following formula: (where c = calibra-
tor and U = unknown and CP = crossing point)
Data was analyzed using the Relative Quantitation soft-
ware (Roche Diagnostics) and is expressed as relative
expression.
Results and Discussion
Effects of UV-irradiation on the proliferation and 
apoptosis of RPMI 8226 cell line
Ultra violet irradiation can be an effective sterile and non-
pharmacological way to induce apoptosis of tumor cells.
Although UV-irradiation of tumor cells results in genoto-
xic damage and death in vitro, in vivo irradiation can result
in impairment of tumor rejection in mice and possibly in
humans due to impairment of the tumor-specific immu-
nocytes [29]. Thus, determining the dose of irradiation for
treating tumors ex vivo is important and preferred over
localized or total body irradiation as a means of reducing
tumor burden and developing effective anti-tumor
immune responses. In order to determine the minimal
dose of UV-irradiation that will inhibit tumor cell growth,
we first compared the effect of different doses (0, 20, 40,
60, 80, 100, 120, 140 or 160 mJ/cm2) of UV-irradiation
on short-term (3 hr) proliferation in the RPMI 8226 MM
cell line. As can be seen in Figure 1, there is a statistically
significant (p < 0.01) dose dependent decrease in tumor
cell growth at all dose levels. These data suggest that the
minimal UV-irradiation dose required to inhibit RPMI
8226 MM cell line growth was 120 mJ/cm2. Thus, at 120
mJ/cm2 dose, the proliferation of RPMI cells is inhibited
by approximately 85% in 3 hours and would therefore
unlikely outgrow the cultures when mixed with PBMC.
Since, lymphocyte priming requires long-term cell co-cul-
ture with UV-irradiated MM cells, we next compared the
effect of different doses (6, 12, 24, 60, 120 or 240 mJ/cm2)
of UV-irradiation on MM cell proliferation for up to 8
weeks. Importantly, a low UV dose that prevents over-
growth of cell cultures by the surviving MM cells but that
still maintain tumor antigen presentation was selected, as
this maneuver would facilitate antigen recognition by T
lymphocytes [30]. The minimal UV- irradiation dose that
will inhibit long-term growth of RPMI 8226 MM cell line
is also 120 mJ/cm2 (data not shown). Hence, this dose of
UV-irradiation was used in subsequent experiments.
For the development of an effective antigen-presentation
dependent vaccine, a treatment that results in apoptosis
and not necrosis of the tumor itself can often be highly
desired [31-34]. Having determined the optimal UV dose
(i.e. 120 mJ/cm2) that would result in growth arrest of the
RPMI 8226 MM cell line, we next determined the time to
Efficiency (h-HSP)CP(hHSP.C-hHSP.U)
Efficiency ( -actin)CP(β b-actin.C-b-actin.U)
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onset of apoptosis of tumor cells following UV-irradia-
tion. As can be seen in Figure 2, 52.4% of RPMI 8226 MM
cells exposed to 120 mJ/cm2 of UV-irradiation demon-
strated cells present in the early phases of apoptosis
(annexin V+PI-) with fewer cells present at the later stage
of apoptosis by two hours post UV-irradiation. However,
by four hours post UV-irradiation, 94.5% of tumor cells
had undergone established apoptosis (annexin V+PI+) and
this was accompanied with by a concomitant decrease in
cells found in early phases of apoptosis. There was also lit-
tle PI-only staining cells by four hours (data not shown),
suggesting that little necrosis has occurred at this point.
These data confirm that UV-irradiation is an effective way
to inhibit proliferation and induce apoptosis of the RPMI
8226 MM cell line, and that apoptosis is best achieved
with a short dose time of UV-irradiation at an optimized
dose of 120 mj/cm2.
Expansion of CD8+ CTLs by UV-irradiated RPMI 8226 MM 
under 'mixed-culture' priming conditions
In order to determine whether optimally UV-irradiated
RPMI 8226 MM cells could be used as whole cell immu-
nogens for PBMC priming, we studied the lymphocyte
subsets that were generated after 10 days of PBMC prim-
ing. Priming was performed with four hour UV-treated
and thus apoptosis-induced MM cells. As can be seen in
Figure 3, priming of PBMCs using UV-irradiated RPMI
8226 MM cells led to a significant (p < 0.01) expansion of
CD8+ CTLs (43.8%) when compared to unprimed PBMCs
(25.7%) or PBMCs primed using mitomycin-treated
RPMI 8226 MM cells (26.2%); together with a reciprocal
decrease in CD4+ CTLs. In addition, there was also a small
increase (4.43%) in the CD8+/CD56+ NK cell population
as compared to unprimed PBMCs (1.16%) or PBMCs
primed using mitomycin-treated RPMI 8226 MM cells
(1.65%). In contrast, mitomycin-treated tumor cell
immunogens were not associated with any significant
expansion of CD4+, CD8+ or CD8+/CD56+ CTLs, when
compared to unprimed PBMCs. This increase in CD8+ CTL
was sustained during the 21-day co-culture and survival
was ensured by the addition of exogenous recombinant
human IL-2 (data not shown) [35].
Efficient CTL redirected lysis of fresh RPMI cells following 
'mixed-culture' T cell priming conditions
In order to determine whether CD8+ CTLs were effective in
eradicating MM cells, we next performed cytotoxic assays
using viable RPMI 8226 MM cells as target cells. As can be
seen in Figure 4, PBMCs primed using UV-irradiated or
mitomycin (mito)-treated RPMI 8226 MM cells in the
'mixed-culture' regimen were effective in eradicating fresh
RPMI 8226 MM. Maximal lysis of RPMI 8226 MM cells
was most marked with PBMC primed with UV-RPMI
(84.65 to 88.19%, median 85.26%) and less marked
Effect of UV-irradiation on apoptosis of RPMI 8226 MM cell lin sFigure 2
Effect of UV-irradiation on apoptosis of RPMI 8226 
MM cell lines. In order to determine the time of onset of 
apoptosis of the RPMI 8226 MM cell line following UV-irradi-
ation, tumor cells were first irradiated with 120 mJ/cm2 of 
UV light and serially (0, 2, 4, 6 and 8 hr post UV-irradiation) 
analyzed for the onset of early apoptosis (annexin V+PI-) or 
established apoptosis (annexin V+PI+) using annexin V-FITC/
PI dual staining and fluorescence flow cytometric analysis. All 
experiments were performed triplicate and expressed as 
mean values.
Effect of UV-irradiation on short-term proliferation of RPMI 8226 MM cell lineFigure 1
Effect of UV-irradiation on short-term proliferation 
of RPMI 8226 MM cell line. The RPMI 8226 MM cell line 
was irradiated using UV light (0, 20, 40, 60, 80, 100, 120, 140 
or 160 mJ/cm2) and assessed for DNA synthesis using stand-
ard 3H-TdR (0.25 μCi/well) incorporation assays 3 hr after 
UV-irradiation. Three triplicate experiments were per-
formed and data is shown as box plots. Statistical differences 
were determined using the Mann-Whitney test.
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when primed with mito-RPMI (82.59 to 83.80%, median
83.33%), although the difference was not statistically sig-
nificant (p = 0.18). UV-RPMI or mito-RPMI primed PBMC
demonstrated maximal lysis, which was significantly (p <
0.001) more than the unprimed PBMC (38.02% to
43.19%, median 42.38). These results indicate that the
priming of allogeneic PBMC with UV irradiated MM cells
results in the marked anti-tumor cytolytic activity, which
is at least as good as the priming with mitomycin, inacti-
vated MM cells. When the primed cells were co-cultured
with autologous PBMC cells, little RPMI directed cytotoxic
cell lysis was seen (data not shown).
Up regulation of heat shock protein expression on RPMI-
8226 cells following UV-irradiation
Since the upregulation of heat shock protein (HSP)/
molecular chaperones, especially Grp94 and 78, can pro-
mote the antigenicity of tumor cells and since ultraviolet
irradiation can potentially induce the expression of HSPs;
we went on to investigate if the same doses of UV-irradia-
tion resulted in an increase in heat shock proteins on the
RPMI tumor cells. Upon western blot analysis, expression
of the cytosolic HSP-70 protein, Grp78, was increased
after UV-irradiation at a dose of 120 mJ/cm2 by two hours
(Figure 5A). Using polyclonal goat antibodies reactive
against the endoplasmic reticulum HSP-90 protein,
Grp94, there was a marked increase in the two faster
migrating bands that reacted with the anti-Grp antibody
(Figure 5B). Although there was no change in the slower
migrating bands recognized by our anti-Grp94 antibod-
ies, there was an increase in the total amount of Grp94
seen by Western immunoblotting. This increase was tran-
sient and reached a maximum by four hours. Due to the
observed slight transient increase in the Actin levels, inte-
grated density values were determined and the Grp94
density was calculated after normalization with Actin at
each condition. The values still showed a transient
increase in Grp94 (values were 0.851, 2.09, 3.25, 2.38,
1.09, and 0.777 for each time point).
In order to determine if UV-irradiation was accompanied
by an increase in heat shock protein mRNA expression,
relative expression of grp94 and grp78 mRNA before and
after UV-irradiation by quantitative real-time polymerase
chain reaction (RT-PCR) was performed. As seen in Figure
6A, grp78 mRNA expression rapidly increased 17-fold by
1 hour after 120 mJ/cm2 UV-irradiation, falling off by 2
hours. Similarly, grp94 mRNA expression increased 12.3-
fold 1 hour after UV-irradiation, subsequently decreasing
by 2 hours post UV treatment (Figure 6B). Thus, UV-irra-
diation induces early heat shock protein message expres-
sion followed later by cell protein expression.
Redirected CTL assay against RPMI following mixed culture conditions with UV-primed RPMI cellsFigure 4
Redirected CTL assay against RPMI following mixed 
culture conditions with UV-primed RPMI cells. Nor-
mal donor PBMCs were primed using UV-irradiated (120 mJ/
cm2) or mitomycin-treated (100 μg/mL) RPMI 8226 MM cells 
as whole cell immunogens for 28 days in 'mixed-culture con-
ditions'. Non-primed, mito-primed, or UV-primed and 
PBMCs (effector cells) were then co-cultured with viable 3H-
TdR-labeled RPMI 8226 MM cells (target cells) in a re-
directed CTL assay. A standard 3H-TdR cytotoxicity assays 
was performed at E:T ratios of 1:1, 3:1, 6:1, 12:1 or 25:1, 50:1 
and 100:1.
Expansion of CD8+ CTLs by UV-irradiated RPMI 8226 MM cell whole-cell immunogens in 'mixe  culture' conditionsFigure 3
Expansion of CD8+ CTLs by UV-irradiated RPMI 8226 
MM cell whole-cell immunogens in 'mixed culture' 
conditions. Normal donor PBMCs were primed using UV-
irradiated (120 mJ/cm2) or mitomycin-treated (100 μg/mL) 
RPMI 8226 MM cells as whole cell immunogens for 10 days 
and analyzed for CD4, CD8, CD56, granzyme and perforin 
expression using indirect immunofluorescence flow cytomet-
ric analysis. Unprimed and concurrently cultured PBMCs 
were used as negative controls. Dually positive 
granzyme+perforin+ CTLs were identified gated and specifi-
cally analyzed for CD4+ (open columns), CD8+ (black col-
umns) or CD8+/CD56+ (striped columns) expression.
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Heat shock proteins are expressed in the cell membrane
during cell stress or in abnormal cells such as tumor cells
[36,37] but not in non-neoplastic cells. It is likely that sur-
face expressed heat shock proteins contain immunogenic
peptides that are taken up by receptors on APCs and can
be cross-presented onto cytolytic T lymphocytes [19]. In
order to determine in RPMI cells express Grp78 or Grp94
on their cell surface following UV exposure, the cells were
stained with antibodies against these HSPs and analyzed
by flow cytometry. Although the cells contained a small
amount of both Grp78 (4.25%) and Grp94 (3.9%), both
were dramatically increased upon UV stimulation after
four hours (Figure 7). Therefore, UV-exposure of RPMI
after four hours induces early apoptosis, arrests prolifera-
tion, results in efficient priming of CTL and is accompa-
nied by increased protein and messenger RNA expression
of heat shock proteins Grp78 and 94.
HSP-peptide inhibitors block UV-irradiated RPMI 
recognition by cytolytic T cells
In order to link the upregulation of surface expressed
immunogenic HSPs to increased HSP-dependent immune
recognition by CTL in the 'mixed culture' conditions, the
geldanamycin derivative, 17-AAG was used. Geldanamy-
cin and its analogue 17-allyamino, 17-demethoxygeldan-
amycin (17-AAG) are able to compete with ATP at the
nucleotide binding site in the NH2-terminal domain of
HSP90 and thus inhibit the peptide binding properties of
HSP90 including Grp94 and does so without affecting its
own expression [38,39]. As can be seen in Figure 8, 17-
AAG resulted in a 37% reduction in CTL recognition of
UV-primed RPMI. Although not complete, this suggests
that a portion of the recognition by CTL of UV primed
RPMI cells is a result of HSP-90's client protein properties.
Conclusion
Successful cancer immunotherapy requires the reconstitu-
tion of host tumor immunosurveillance, and the produc-
tion of durable cures through induction of
immunological memory [40]. Although both humoral
and cellular vaccines have been shown to produce cures in
the short term, durable long-term cures are only possible
with cell-based vaccines (e.g. CTL vaccines), because
immunological memory is a cellular function. Unfortu-
nately, the use of autologous CTLs as cellular anti-tumor
vaccines for the treatment of MM has been associated with
a lack of clinical efficacy; and this is widely thought to be
due to the deletion of critical CTL clones that specifically
target the tumor [35,41,42]. Although this may theoreti-
cally be overcome by the use of allogeneic CTL anti-tumor
vaccines, this form of immunotherapy is frequently asso-
ciated with limited [43] to significant [44] graft-versus-
Effect of UV-irradiation on mRNA expression of Grp94 and Grp78 in RPMI 8226 cellsFigure 6
Effect of UV-irradiation on mRNA expression of 
Grp94 and Grp78 in RPMI 8226 cells. RPMI 8226 cells 
were subjected to UV-irradiation at 120 mJ/cm2 and RNA 
was extracted 1, 15, 60 and 120 minutes. Real-time PCR 
using actin and grp78 (A) or grp94 (B) primers was per-
formed and data is expressed as calibrator corrected and 
actin normalized ratios.
Effect of UV-irradiation on total Grp78 and 94 protein expressionFigure 5
Effect of UV-irradiation on total Grp78 and 94 pro-
tein expression. Whole cell lysates of RPMI-8226 cells at 1, 
2, 4, 6, and 8 hours after an UV-irradiation dose of 120 mJ/
cm2, were run on a 12% polyacrylamide gel. Western immu-
noblotting was performed with anti-Grp78 (A) and anti-
Grp94 (B) antibodies and data is representative to two inde-
pendent experiments.
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host-disease (GVHD), and may pose real dangers to the
patient.
A special form of anti-cancer vaccination strategy involves
the introduction of non-cellular tumor rejection mole-
cules or Ag into a mammalian host to induce cellular
immune responses. This vaccination strategy has previ-
ously been shown to be effective in promoting tumor rec-
ognition and rejection in both autologous as well as
allogeneic mice [18,19]. The principal molecules mediat-
ing this process are the HSP molecular chaperones, espe-
cially TRA-1. Tumor rejection Ag-1 is a HSP [18], which
has been shown to mediate tumor rejection in various
cancers [19]. These molecules act to chaperone tumor-
specific peptides to sites in the body where tumor Ag is
most effectively presented, thereby inducing tumor recog-
nition and tumor-specific CTL (both CD8+ as well as NK
cells) activation. Ultraviolet irradiation has also been
shown to result in the presentation of cellular antigens. In
fact, high doses of UV-B irradiation induces proinflamma-
tory apoptosis and necrosis, where the production of
inflammatory cytokines is accompanied by exposure and
release of autoantigens and autoimmune disease [45].
In the present study, UV-irradiation was used to enhance
the immunogenicity of MM cells while at the same time
inducing apoptosis of the tumor cells. Ultraviolet light-
induced Fas expression may serve to target stress-injured
cells for removal by FasL-bearing cells or by FasL produced
by the cells themselves in response to the stimuli, and may
represent a general function of the Fas/FasL pathway in
facilitating the apoptosis and elimination of undesirable
or harmful cells [46]. However, UV-irradiation also
appears to engage the apoptotic axis of TNFR1 [47], and
appears to involve initial formation of the Fas-FADD-cas-
pase-8 death complex in an FasL-independent manner
Redirected CTL assay against RPMI following mixed culture conditions following addit on of 17-AAGFigure 8
Redirected CTL assay against RPMI following mixed 
culture conditions following addition of 17-AAG. Nor-
mal donor PBMCs were primed using UV-irradiated (120 mJ/
cm2) or mitomycin-treated (100 μg/mL) RPMI 8226 MM cells 
as whole cell immunogens for 28 days in 'mixed-culture con-
ditions'. Non-primed, mito-primed, or UV-primed and 
PBMCs (effector cells) were then co-cultured with viable 3H-
TdR-labeled RPMI 8226 MM cells (target cells) in a re-
directed CTL assay. 17-AAG was added at 10 uM to the UV-
irradiated RPMI cells for four hours and then washed away 
before the cells were added to the CTL culture. A standard 
3H-TdR cytotoxicity assays was performed at E:T ratio of 
50:1. Experiments were performed triplicate and expressed 
as the mean ± 2SEM.
Cell surface expression of MHC molecules afterUV-irradia-tionFigure 7
Cell surface expression of MHC molecules afterUV-
irradiation. RPMI-8226 cells were subjected to 120 mJ/cm2 
of UV-irradiation. Cells were then stained with anti-Grp94 
and anti-Grp78 antibodies. The figures show a plot of side 
scatter on the vertical axis versus FL-1 on the horizontal axis 
of the dot plot. Cells were stained with anti-CD45 (as con-
trol (A)), anti-Grp94 (B), and anti-Grp78 (C) following four 
hours of unstimulated or UV-irradiated conditions.
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[48]. Some types of chemotherapeutic drugs such as
anthracyclins, as well as UV-C irradiation, can lead to the
cell surface expression of calreticulin (CRT) which has
recently been shown to confer anti-tumor immunogenic-
ity to otherwise less immunogenic tumor cells [32]. It will
be interesting to see if UV- irradiation of MM cells, as was
done in this study, also leads to the surface expression of
CRT. Furthermore, the expression of costimulatory mole-
cules on dendritic cells (DC) is upregulated after co-incu-
bation with UV-irradiated tumor cells, and UV-irradiated
tumor cells-pulsed DCs stimulated allogeneic T lym-
phocytes more efficiently than DCs pulsed with γ-irradi-
ated cells [49]. This increase in the ability of human
cancer cells to induce CTLs by UV-irradiation has been
found to be independent of the corresponding effect on
histocompatibility locus Ag (HLA) expression [50]. In par-
allel with the induction of tumor cell immunogenicity,
UV-irradiation made tumor cells more sensitive to natural
killer cell-mediated cytotoxicity and to lysis by TNF, sug-
gesting that immunogenicity and TNF sensitivity are two
independent UV-induced properties [51]. It is important
to note however, that the effects of mitomycin C treat-
ment on MM cells did not alter the Grp94 or Grp78
expression significantly nor did it result in early induction
of apoptosis (data not shown) and thus it served as our
control in our CTL assays. The effects of 17-AAG were not
tested on mitomycin treated MM cells.
When allogeneic PBMCs were exposed to these UV-irradi-
ated MM cells, through the process of repetitive priming,
CD8+ CTLs were induced. Furthermore, these CTLs dem-
onstrated strong tumor-specific activity. These data there-
fore confirm that not only were cytolytic NK cells
preferentially induced, but that these CTLs were function-
ally reactive in targeting co-cultured tumor cells as well. In
addition, since CTLs are widely thought to be the princi-
pal mediators of host tumor immunosurveillance [7],
these data further suggest that this vaccination strategy
could both reconstitute host tumor immunosurveillance
as well as mediate immunological memory; i.e. be the
'Holy Grail' of cancer immunotherapy.
In conclusion, our study has shown in a functional way
that it is feasible to devise an autologous cell-based anti-
cancer vaccine using UV-irradiated MM cells as immuno-
gens. Primed CTLs were associated with significant eradi-
cation of co-cultured MM cells, demonstrating in a
functional and efficacious method to promote tumor
rejection. Finally, since UV-irradiation increases HSP
expression, we therefore postulate that the mechanism for
CTL priming involves the induction of tumor peptide-
loaded HSP expression on the surface of UV-irradiated
MM cells, which in turn preferentially induced cytolytic T
cell activation. Our study, therefore, provides the frame-
work for the development of preclinical and clinical stud-
ies using anti-tumor cytolytic T cell vaccines for treating
MM, and in which UV-irradiated tumor cells are used as
immunogens.
List of abbreviations
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